Just reported
From Resmed's results release of 29 octobre 2026; its quarterly report has since been filed.
Actual
1,41B $US
+5,9 % y/y
-3,3 % q/q
Guided
—
No guide given
Actual
2,92 $US
+23 % y/y
+11 % q/q
Guided
—
No guide given
Actual
453M $US
+1,4 % y/y
+1,0 % q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Resmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Les parts du chiffre d'affaires sont des estimations pour quarter ended 2026-03-31, pas des chiffres tirés d'un document officiel.
AirSense 11
A connected machine that delivers continuous or automatically adjusted air pressure to treat sleep apnea.
AirCurve 11
A bilevel breathing machine that provides different pressure levels for breathing in and out, for people needing more support or with complex breathing disorders.
Astral ventilators
Ventilators that provide breathing support, including for people receiving care at home.
AirTouch N30i, AirTouch F30i, and AirFit F40 masks
Masks that connect a person to a breathing machine during sleep; the named models include fabric and silicone designs.
myAir and AirView
Software for patients to engage with their sleep treatment and for providers to connect with and support patients.
Brightree and MEDIFOX DAN
Software products for residential care and home medical equipment providers.
ResMed makes devices that help people breathe during sleep and ventilators for people who need breathing support. It also sells masks and software for patients, medical equipment providers, and residential care providers. Its sleep products include machines that connect with patient and provider software.
Construit à partir des documents déposés par Resmed Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
239,53 $US+0,2 %clôture 13 nov.
Chiffres jusqu’au 30 septembre 2026, issus du 10-Q déposé le 30 octobre 2026
ResMed sells breathing machines and masks for sleep apnea and other breathing disorders to patients through medical equipment providers.
Grade B+
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 41 de l’historique des notes de Resmed Inc.. Les 39 autres remontent jusqu’à octobre 2016.